Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis

Opis bibliograficzny
Główni autorzy:	Sørensen, P, Deisenhammer, F, Duda, P, Hohlfeld, R, Myhr, K, Palace, J, Polman, C, Pozzilli, C, Ross, C
Format:	Journal article
Język:	English
Wydane:	Wiley-Blackwell 2010

Podobne zapisy

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.
od: Sørensen, P, i wsp.
Wydane: (2005)

THE INFLUENCE OF NEUTRALIZING ANTIBODIES TO INTERFERON-BETA ON PROGRESSION OF MULTIPLE SCLEROSIS
od: V. Yu. Lizhdvoy, i wsp.
Wydane: (2016-07-01)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
od: Delphine Bachelet, i wsp.
Wydane: (2016-01-01)

Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.
od: Sonia Gavasso, i wsp.
Wydane: (2014-01-01)

Beta-interferons in multiple sclerosis
od: Aggarwal Sourabh, i wsp.
Wydane: (2010-01-01)

Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
od: Lampasona, V, i wsp.
Wydane: (2003)

beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis
od: Parry, A, i wsp.
Wydane: (2002)

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
od: Parry, A, i wsp.
Wydane: (2003)

Interferon beta treatment of multiple sclerosis.
od: Markovitz, D
Wydane: (1994)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
od: Mohamed Rayen Ganouni, i wsp.
Wydane: (2023-10-01)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
od: Cefaro Luca, i wsp.
Wydane: (2009-10-01)

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
od: Barletta Valeria, i wsp.
Wydane: (2011-02-01)

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
od: Jenny Link, i wsp.
Wydane: (2017-01-01)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
od: Sibley, W, i wsp.
Wydane: (1994)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
od: Clerico, M, i wsp.
Wydane: (2008)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
od: Clerico, M, i wsp.
Wydane: (2008)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
od: Sarah Burkill, i wsp.
Wydane: (2019-01-01)

MOTOR SKILL LEARNING IN MULTIPLE SCLEROSIS
od: Tomassini, V, i wsp.
Wydane: (2009)

Review: Neutralizing antibodies against interferon-beta
od: Per Soelberg Sorensen
Wydane: (2008-09-01)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
od: Filippini, G, i wsp.
Wydane: (2003)

Treatment of multiple sclerosis with interferon beta-1 b.
od: Abdul-Ahad, A, i wsp.
Wydane: (1997)

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
od: Jenny Link, i wsp.
Wydane: (2014-01-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
od: Petkau, A, i wsp.
Wydane: (2004)

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
od: Mahe J, i wsp.
Wydane: (2013-08-01)

Functional correlates of motor learning in multiple sclerosis
od: Tomassini, V, i wsp.
Wydane: (2009)

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
od: Lisa G M van Baarsen, i wsp.
Wydane: (2008-04-01)

Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy
od: C. Carbonelli, i wsp.
Wydane: (2015-12-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
od: Petkau, A, i wsp.
Wydane: (2004)

Treatment of multiple sclerosis with interferon beta-1b - Reply
od: Sibley, W, i wsp.
Wydane: (1997)

A cost-utility analysis of interferon beta for multiple sclerosis.
od: Parkin, i wsp.
Wydane: (1998-01-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
od: Masoud Mohammad Malekzadeh, i wsp.
Wydane: (2020-06-01)

The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis
od: Ebers, G, i wsp.
Wydane: (1997)

Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis
od: E Gibbons, i wsp.
Wydane: (2015-01-01)

Relating brain damage to brain plasticity in patients with multiple sclerosis.
od: Tomassini, V, i wsp.
Wydane: (2012)

Designing of an ELISA Method for the Measurement of Serum Antibodies against Interferon-beta and the Study of the Frequency of these Antibodies in Patients with Multiple Sclerosis Treated with CinnoVex
od: Nasrin Zare, i wsp.
Wydane: (2012-11-01)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
od: Damiano Paolicelli, i wsp.
Wydane: (2016-01-01)

Preservation of motor skill learning in patients with multiple sclerosis
od: Tomassini, V, i wsp.
Wydane: (2011)

Preservation of motor skill learning in patients with multiple sclerosis.
od: Tomassini, V, i wsp.
Wydane: (2011)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
od: Ebers, G, i wsp.
Wydane: (1998)

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
od: Duquette, P, i wsp.
Wydane: (1996)